Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Watchlisten für Ihre Werte
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON
  1. Startseite
  2. Aktien
  3. Schweiz
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Andere Sprachen
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen
Nachrichten in anderen Sprachen über BASILEA PHARMACEUTICA AG
24.01.Basilea Pharmaceutica's Derazantinib Shows High Disease Control Rate in Bile Duct Cance..
24.01.BASILEA PHARMACEUTICA : Updated January 24, 2022
24.01.Basilea reports updated interim results for iCCA patients with FGFR2 mutations and ampl..
24.01.Basilea Reports Updated Interim Results for iCCA Patients with FGFR2 Mutations and Ampl..
13.01.BASILEA : le Cresemba aussi autorisé contre l'aspergillose invasive en Chine
13.01.Basilea-Pfizer's Cresemba Gets China's Approval to Treat Another Fungal Infection
13.01.Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergi..
13.01.Basilea announces approval of antifungal Cresemba(R) (isavuconazole) for invasive asper..
11.01.Basilea boucle le recrutement pour une étude contre le staphylocoque doré
11.01.Basilea Completes Patient Enrolment For New Antibiotic Study
11.01.BASILEA PHARMACEUTICA : Updated January 11, 2022
11.01.Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigat..
11.01.Basilea Announces Completion of Patient Enrolment in Phase 3 Eradicate Study Investigat..
10.01.Basilea prévoit des recettes meilleures que prévu pour 2021
10.01.Basilea Pharmaceutica's Preliminary FY21 Revenue Beats Estimates
10.01.BASILEA PHARMACEUTICA : Updated January 10, 2022
10.01.Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-positi..
10.01.Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2021
07.01.L'ombre d'un doute
07.01.EN DIRECT DES MARCHÉS : STMicroelectronics, Orange, Sanofi, Air France-KLM, Samsung, NYT, ..
07.01.Basilea reçoit un nouveau paiement d'étape de la part d'Astellas
07.01.BASILEA PHARMACEUTICA : Updated January 07, 2022
07.01.Basilea To Get $16 Million From Astellas After Strong Antifungal Drug Sales In US
07.01.Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million s..
07.01.Strong Cresemba(R) (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million..
06.01.Basilea Expects Late-Stage Data for Anti-Bacterial Drug by Mid-2022
06.01.BASILEA PHARMACEUTICA : Updated January 06, 2022
06.01.Basilea reports on portfolio progress made in 2021
2021Basilea reçoit un nouveau paiement d'étape de la part de Pfizer
2021Basilea Gets $10 Million From Pfizer After Chinese Approval of Antifungal Cresemba
2021Basilea receives USD 10 million milestone payment related to approval of antifungal Cre..
2021Basilea receives USD 10 million milestone payment related to approval of antifungal Cre..
2021Basilea obtient l'autorisation de la FDA pour une étude clinique
2021BASILEA PHARMACEUTICA : Updated December 17, 2021
2021Basilea Wins US FDA Nod For Early-Stage Study Of New Cancer Drug
2021Basilea announces FDA approval of Investigational New Drug application for novel oncolo..
2021Basilea Pharmaceutica Ltd. Announces FDA Approval of Investigational New Drug Applicati..
2021Basilea touche son deuxième versement de Pfizer pour Cresemba en 12 mois
2021Basilea Pharmaceutica Receives $10 Million Milestone Payment from Pfizer
2021Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 10 million sales..
2021Continued strong Cresemba(R) (isavuconazole) sales by Pfizer trigger USD 10 million sal..
2021Basilea poursuit son expansion dans l'oncologie
2021Basilea Seeks US FDA's Investigational New Drug Approval For Cancer Therapy
2021BASILEA PHARMACEUTICA : Updated November 16, 2021
2021Basilea announces submission of Investigational New Drug application for novel oncology..
2021Basilea Pharmaceutica Ltd Announces Submission of Investigational New Drug Application ..
2021BASILEA PHARMACEUTICA : Therapy Shows Synergistic Anti-Tumor Effects In Gastric Cancer Mod..
2021Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gas..
2021Basilea Pharmaceutica Ltd Presents Preclinical Data on Synergy Between Derazantinib and..
2021BASILEA PHARMACEUTICA : Asahi Kasei Seek Japanese Nod For Anti-Fungal Drug
2021BASILEA : demande d'homologation au Japon pour le Cresemba
2021Basilea's partner Asahi Kasei Pharma filed New Drug Application for the marketing autho..
2021BASILEA PHARMACEUTICA : partner Asahi Kasei Pharma filed New Drug Application for the mark..
2021BASILEA : durée de vie prolongée avec dérazantinib
2021BASILEA PHARMACEUTICA : Bile Duct Cancer Drug Shows Improved Efficacy In Updated Mid-Stage..
2021Basilea presents full safety and efficacy data set on derazantinib in patients with FGF..
2021Basilea Pharmaceutica Ltd. Presents Full Safety and Efficacy Data Set on Derazantinib i..
2021Basilea Pharmaceutica Ag Reports Earnings Results for the Half Year Ended June 30, 2021
2021Basilea modère son estimation de perte pour 2021
2021BASILEA PHARMACEUTICA : reports strong financial results for half-year 2021 with significa..
2021Basilea Pharmaceutica AG Provides Earnings Guidance for the Full Year 2021
2021Basilea obtient des fonds supplémentaires pour développer Ceftobiprol
2021BASILEA PHARMACEUTICA : Wins Additional $4.3 Million US Funding to Develop Antibiotic
2021Basilea awarded additional USD 4.3 million by BARDA to support phase 3 development of c..
2021BASILEA PHARMACEUTICA : Gets US FDA's Orphan Drug Designation For Brain Cancer Treatment
2021Basilea obtient le statut de "médicament orphelin" pour le lisavanbulin
2021Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the trea..
2021BASILEA : Asahi Kasei revendique un succès clinique avancé sur l'isavuconazole
2021BASILEA PHARMACEUTICA : Partner to File Marketing Authorization for Antifungal Drug in Jap..
2021BASILEA : Asahi Kasei vise une extension d'indication pour isavuconazole au Japon
2021Basilea's partner Asahi Kasei Pharma prepares NDA filing for the marketing authorizatio..
2021BASILEA PHARMACEUTICA : partner Asahi Kasei Pharma prepares NDA filing for the marketing a..
2021Certain Shares of Basilea Pharmaceutica AG are subject to a Lock-Up Agreement Ending on..
2021Basilea s'appuiera sur JSC Lancet pour distribuer l'antibiotique Zevtera
2021BASILEA PHARMACEUTICA : Enters Deal For Distribution Of Antibiotic In Russia, Eurasian Eco..
1  2  3  4  5  6  7  8  9Weiter
Anstehende Termine für BASILEA PHARMACEUTICA AG